SMART-ID BSI Assay
Rapid identification of bloodstream infection pathogens (Sepsis)
DevelopmentActive
Key Facts
Indication
Rapid identification of bloodstream infection pathogens (Sepsis)
Phase
Development
Status
Active
Company
About Scanogen
Scanogen is a private, pre-revenue diagnostics company pioneering a rapid, culture-free solution for sepsis diagnosis. Its SMART-ID BSI Assay, which has received FDA Breakthrough Device designation, aims to identify pathogens directly from whole blood in two hours, a dramatic improvement over the 1-2 day standard of blood cultures. The company's S1 Instrument is a modular, benchtop system designed for near-patient use in emergency departments and hospital labs. If successful, Scanogen's technology could significantly improve sepsis outcomes, reduce hospital costs, and combat antimicrobial resistance.
View full company profile